ArticleNeurology2017
Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.
Abstract read
In one paragraph
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- A world view: Considerations of sociocultural diversity in the study of subjective cognitive decline in Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Differential Item Functioning and Clinical Utility of the Subjective Memory Complaints Questionnaire in a Multi-Ethnic Cohort.Dementia and geriatric cognitive disorders · 2025Article
- Basal forebrain volume and metabolism in carriers of the Colombian mutation for autosomal dominant Alzheimer's disease.Scientific reports · 2024Article
- Subjective Cognitive Decline and Genetic Propensity for Dementia beyond Apolipoprotein εCurrent issues in molecular biology · 2024Review
- Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation.Journal of Alzheimer's disease : JAD · 2024Review
- Longitudinal relationships between grip strength, subjective memory complaints and cognitive function among middle-aged and older adults in China.Aging clinical and experimental research · 2023Article
- Associations Among Loneliness, Purpose in Life and Subjective Cognitive Decline in Ethnoracially Diverse Older Adults Living in the United States.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2023Article
- Subjective Cognitive Decline and its Relation to Verbal Memory and Sex in Cognitively Unimpaired Individuals from a Colombian Cohort with Autosomal-Dominant Alzheimer's Disease.Journal of the International Neuropsychological Society : JINS · 2022Article
- Troubled past: A critical psychometric assessment of the self-report Survey of Autobiographical Memory (SAM).Behavior research methods · 2022Article
- Dementia in Latin America: Paving the way toward a regional action plan.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat): Driving Multicentric Research and Implementation Science.Frontiers in neurology · 2021Review
- Article
- Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?The journal of prevention of Alzheimer's disease · 2021Article
- Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease.JAMA network open · 2020Article
- Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis.Alzheimer's research & therapy · 2020Article
- Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.Molecular neurodegeneration · 2020Review
- Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease.Alzheimer's research & therapy · 2020Article
- Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease.Journal of neurology, neurosurgery, and psychiatry · 2020Article
- Hippocampal Resting-State Functional Connectivity Patterns are More Closely Associated with Severity of Subjective Memory Decline than Whole Hippocampal and Subfield Volumes.Cerebral cortex communications · 2020Article
- Spermidine/spermine-NAlzheimer's research & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Daniel J NortonFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Rebecca AmariglioFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Hillary ProtasFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Kewei ChenFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Daniel C Aguirre-AcevedoFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Brendan PulsiferFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Gabriel CastrillonFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Victoria TiradoFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Claudia MunozFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Pierre TariotFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Jessica B LangbaumFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Eric M ReimanFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Francisco LoperaFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Reisa A SperlingFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA.
Yakeel T QuirozFrom Massachusetts General Hospital (D.J.N., R.A., B.P., R.A.S., Y.T.Q.); Harvard Medical School (D.J.N., R.A., R.A.S., Y.T.Q.); Center for Alzheimer Research and Treatment, Brigham and Women's Hospital (R.A., R.A.S.), Boston, MA; Banner Alzheimer's Institute (H.P., K.C., P.T., J.B.L., E.M.R.), Phoenix, AZ; Grupo de Neurociencias (D.C.A.-A., V.T., C.M., F.L., Y.T.Q.), Universidad de Antioquia; Instituto de Alta Tecnologia Medica (G.C.), Medellin, Colombia; and Athinoula A Martinos Center for Biomedical Imaging (Y.T.Q.), Boston, MA. yquiroz@mgh.harvard.edu.
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MRECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6MTHE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GOMEZ-ISLA, TERESA · 1985 to 2018
$42.1MAlzheimer's Prevention Initiative ADAD Colombia TrialR01AG055444 · NIA · BANNER HEALTH · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2017 to 2022
$14.9MEvolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6MImaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI XIONG, CHENGJIE · 2008 to 2009
$6.1MCharacterizing the Evolution of Amyloid Deposition in Normal ElderlyR01AG037497 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSON, KEITH A. · 2010 to 2014
$3.2MNeural Processes Underlying Cognitive AgingR01AG034556 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BUCKNER, RANDY L · 2009 to 2013
$2.7MMemory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3MMentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4MOptimizing measures of subjective and objective decline in preclinical ADK23AG044431 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AMARIGLIO, REBECCA E · 2014 to 2018
$742kNIA NIH HHS K23 AG044431NIA NIH HHS K24 AG035007NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG027435NIA NIH HHS R01 AG034556NIA NIH HHS R01 AG037497NIA NIH HHS R01 AG055444NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG010483NIH HHS DP5 OD019833
Abstract
objectiveTo cross-sectionally study subjective memory complaints (SMC) in autosomal dominant Alzheimer disease (ADAD).
methodsWe examined self-reported and study partner-based SMC in 52 young, cognitively unimpaired individuals from a Colombian kindred with early-onset ADAD. Twenty-six carried the
resultsSelf-reported SMC were greater in carriers than noncarriers (
conclusionsCognitively unimpaired
Indexed as
AdultAge FactorsAlzheimer DiseaseCognition DisordersCross-Sectional StudiesFemaleHippocampusHumansImaging, Three-DimensionalMagnetic Resonance ImagingMaleMemory DisordersMiddle AgedNeuropsychological TestsPolymorphism, Single NucleotidePresenilin-1Presenilin-1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.